Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

606 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting BRAF for patients with melanoma.
Arkenau HT, Kefford R, Long GV. Arkenau HT, et al. Among authors: long gv. Br J Cancer. 2011 Feb 1;104(3):392-8. doi: 10.1038/sj.bjc.6606030. Epub 2010 Dec 7. Br J Cancer. 2011. PMID: 21139585 Free PMC article. Review.
Intra-patient heterogeneity of BRAF mutation status: fact or fiction?
Menzies AM, Wilmott JS, Long GV, Scolyer RA. Menzies AM, et al. Among authors: long gv. Br J Cancer. 2014 Oct 14;111(8):1678-9. doi: 10.1038/bjc.2013.796. Epub 2013 Dec 24. Br J Cancer. 2014. PMID: 24366302 Free PMC article. No abstract available.
Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.
Carlino MS, Haydu LE, Kakavand H, Menzies AM, Hamilton AL, Yu B, Ng CC, Cooper WA, Thompson JF, Kefford RF, O'Toole SA, Scolyer RA, Long GV. Carlino MS, et al. Among authors: long gv. Br J Cancer. 2014 Jul 15;111(2):292-9. doi: 10.1038/bjc.2014.287. Epub 2014 Jun 10. Br J Cancer. 2014. PMID: 24918823 Free PMC article.
Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma.
Tetzlaff MT, Adhikari C, Lo S, Rawson RV, Amaria RN, Menzies AM, Wilmott JS, Ferguson PM, Ross MI, Spillane AJ, Vu KA, Ma J, Ning J, Haydu LE, Saw RPM, Wargo JA, Tawbi HA, Gershenwald JE, Long GV, Davies MA, Scolyer RA. Tetzlaff MT, et al. Among authors: long gv. Ann Oncol. 2020 Nov;31(11):1569-1579. doi: 10.1016/j.annonc.2020.07.016. Epub 2020 Jul 31. Ann Oncol. 2020. PMID: 32739408 Free article.
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial.
Menzies AM, Ashworth MT, Swann S, Kefford RF, Flaherty K, Weber J, Infante JR, Kim KB, Gonzalez R, Hamid O, Schuchter L, Cebon J, Sosman JA, Little S, Sun P, Aktan G, Ouellet D, Jin F, Long GV, Daud A. Menzies AM, et al. Among authors: long gv. Ann Oncol. 2015 Feb;26(2):415-21. doi: 10.1093/annonc/mdu529. Epub 2014 Nov 18. Ann Oncol. 2015. PMID: 25411413 Free article. Clinical Trial.
606 results